La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Cytosorbents Résultats passés
Passé contrôle des critères 0/6
Cytosorbents's earnings have been declining at an average annual rate of -15.7%, while the Medical Equipment industry saw earnings growing at 11.2% annually. Revenues have been growing at an average rate of 5.3% per year.
Informations clés
-15.7%
Taux de croissance des bénéfices
-7.6%
Taux de croissance du BPA
Medical Equipment Croissance de l'industrie | 8.9% |
Taux de croissance des recettes | 5.3% |
Rendement des fonds propres | -152.5% |
Marge nette | -68.7% |
Dernière mise à jour des bénéfices | 30 Jun 2024 |
Mises à jour récentes des performances passées
Recent updates
Investors Continue Waiting On Sidelines For Cytosorbents Corporation (NASDAQ:CTSO)
Jul 04Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?
Mar 16Take Care Before Jumping Onto Cytosorbents Corporation (NASDAQ:CTSO) Even Though It's 28% Cheaper
Jan 06Is Cytosorbents (NASDAQ:CTSO) Using Too Much Debt?
Nov 10Shareholders Should Be Pleased With Cytosorbents Corporation's (NASDAQ:CTSO) Price
Jul 13Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?
May 16We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate
Mar 08CytoSorbents secures $4.3M contract by U.S. Department of Defense
Oct 06CytoSorbents stock rises on US DoD contract to develop device for universal plasma
Sep 09We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate
Sep 02CytoSorbents gets reimbursement for CytoSorb in Turkey
Aug 23CytoSorbents stock rises 10% as Israel approves coverage for CytoSorb system
Aug 17Cytosorbents GAAP EPS of -$0.25 misses by $0.13, revenue of $8.5M misses by $1.06M
Aug 02Ventilation des recettes et des dépenses
Comment Cytosorbents gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
---|---|---|---|---|
30 Jun 24 | 37 | -26 | 37 | 12 |
31 Mar 24 | 37 | -28 | 37 | 14 |
31 Dec 23 | 36 | -29 | 37 | 16 |
30 Sep 23 | 37 | -23 | 36 | 15 |
30 Jun 23 | 36 | -26 | 36 | 15 |
31 Mar 23 | 35 | -31 | 36 | 15 |
31 Dec 22 | 35 | -33 | 37 | 15 |
30 Sep 22 | 36 | -41 | 39 | 18 |
30 Jun 22 | 38 | -36 | 38 | 19 |
31 Mar 22 | 41 | -29 | 40 | 18 |
31 Dec 21 | 43 | -25 | 38 | 16 |
30 Sep 21 | 44 | -16 | 37 | 13 |
30 Jun 21 | 45 | -10 | 36 | 10 |
31 Mar 21 | 43 | -9 | 33 | 9 |
31 Dec 20 | 41 | -8 | 32 | 9 |
30 Sep 20 | 36 | -11 | 29 | 10 |
30 Jun 20 | 32 | -17 | 28 | 11 |
31 Mar 20 | 28 | -18 | 26 | 12 |
31 Dec 19 | 25 | -19 | 24 | 12 |
30 Sep 19 | 24 | -21 | 24 | 11 |
30 Jun 19 | 23 | -17 | 22 | 10 |
31 Mar 19 | 23 | -19 | 23 | 8 |
31 Dec 18 | 23 | -17 | 23 | 8 |
30 Sep 18 | 21 | -15 | 21 | 7 |
30 Jun 18 | 19 | -14 | 21 | 6 |
31 Mar 18 | 17 | -10 | 18 | 4 |
31 Dec 17 | 15 | -9 | 16 | 3 |
30 Sep 17 | 14 | -11 | 15 | 3 |
30 Jun 17 | 12 | -10 | 14 | 4 |
31 Mar 17 | 11 | -11 | 13 | 4 |
31 Dec 16 | 10 | -12 | 13 | 4 |
30 Sep 16 | 8 | -9 | 10 | 4 |
30 Jun 16 | 7 | -10 | 10 | 4 |
31 Mar 16 | 6 | -5 | 9 | 4 |
31 Dec 15 | 5 | -9 | 8 | 4 |
30 Sep 15 | 4 | -17 | 8 | 4 |
30 Jun 15 | 4 | -17 | 7 | 4 |
31 Mar 15 | 4 | -21 | 7 | 3 |
31 Dec 14 | 4 | -19 | 6 | 2 |
30 Sep 14 | 4 | -9 | 5 | 1 |
30 Jun 14 | 4 | -8 | 5 | 1 |
31 Mar 14 | 3 | -7 | 4 | 1 |
31 Dec 13 | 2 | -7 | 3 | 2 |
30 Sep 13 | 2 | -7 | 3 | 2 |
Des revenus de qualité: CTSO is currently unprofitable.
Augmentation de la marge bénéficiaire: CTSO is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: CTSO is unprofitable, and losses have increased over the past 5 years at a rate of 15.7% per year.
Accélération de la croissance: Unable to compare CTSO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: CTSO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (5.5%).
Rendement des fonds propres
ROE élevé: CTSO has a negative Return on Equity (-152.54%), as it is currently unprofitable.